Establishing Growth Factor Norms in Healthy Spanish Children
Background
The Insulin-like Growth Factor 1 (IGF-1) system, including its binding proteins IGFBP-3 and Acid-Labile Subunit (ALS), plays a crucial role in childhood growth and metabolism. Accurate normative reference ranges for these biomarkers are essential for diagnosing and managing conditions like IGF-1 deficiency and other growth disorders. However, such comprehensive data, specifically tailored to a healthy pediatric Spanish population, has been historically limited, creating a significant diagnostic gap.
Study Design
Results
While the abstract for this terminated study (NCT01676090) does not present the specific numerical findings, the research was designed to generate crucial normative data for growth factor assessment. The primary outcome focused on establishing IGF-1 levels across various age groups, sexes, and pubertal stages within the healthy Spanish pediatric cohort. Secondary outcomes similarly aimed to define reference ranges for IGFBP-3 and ALS, providing a holistic view of the IGF-1 system components. The core finding, once published, would be the comprehensive set of age-, sex-, and pubertal stage-specific normative ranges for IGF-1, IGFBP-3, and ALS in this specific population. These established ranges would offer a vital benchmark for clinicians, allowing for more accurate interpretation of individual patient results against a relevant healthy population.
Why It Matters
The establishment of accurate normative ranges for IGF-1, IGFBP-3, and ALS is profoundly important for pediatric endocrinology. These reference values provide clinicians with the necessary tools to differentiate between normal physiological variations and pathological conditions like growth hormone deficiency or IGF-1 deficiency, which can manifest as short stature. Having population-specific data significantly improves diagnostic accuracy and guides appropriate therapeutic interventions, potentially leading to earlier and more effective treatment for affected children. This foundational data is critical for future clinical trials and for refining diagnostic algorithms in diverse populations.